Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

MAGNEVIST

GADOPENTETATE DIMEGLUMINE

Standard Dose
469.01MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview MAGNEVIST is listed in Drugs@FDA under application 019596 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient GADOPENTETATE DIMEGLUMINE Form and strength INJECTABLE;INJECTION - 469.01MG/ML Sponsor BAYER HLTHCARE Submission history Latest submission status date: 2018-07-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview MAGNEVIST is listed in Drugs@FDA under application 019596 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient GADOPENTETATE DIMEGLUMINE Form and strength INJECTABLE;INJECTION - 469.01MG/ML Sponsor BAYER HLTHCARE Submission history Latest submission status date: 2018-07-25 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.